Biomarkers, the molecular gaze and the transformation of cancer survivorship

BioSocieties

Volumn 8, Issue 2, 2013, Pages 124-143

  Bell, Kirsten ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

cancer; molecular biomarkers; molecular gaze; risk; subjectivity; tertiary prevention

Indexed keywords

EID: 84878594735     PISSN: 17458552     EISSN: 17458560     Source Type: Journal    
DOI: 10.1057/biosoc.2013.6     Document Type: Article

References (89)

1. Ablin, R.J. (2010) The great prostate mistake. New York Times, 9 March, http://www.nytimes.com/2010/03/ 10/opinion/10Ablin.html?-r=1, accessed 13 May 2012.
2. Adelsward, V. and Sachs, L. (1996) The meaning of 6.8: Numeracy and normality in health information talks. Social Science and Medicine 43(8): 1179-1187. (Pubitemid 26335276)
3. Armstrong, D. (1995) The rise of surveillance medicine. Sociology of Health & Illness 17(3): 393-404.
4. Armstrong, D. (2012) Screening: Mapping medicine's temporal spaces. Sociology of Health & Illness 34(2): 177-193.
5. Armstrong, N. and Eborall, H. (2012) The sociology of medical screening: Past, present and future. Sociology of Health & Illness 34(2): 161-176.
6. Aronowitz, R.A. (2009) The converged experience of risk and disease. Milbank Quarterly 87(2): 417-442.
7. Aronowitz, R. (2010) Gardasil: A vaccine against cancer and a drug to reduce risk. In: K. Wailoo, J. Livingston, S. Epstein and R. Aronowitz (eds.) Three Shots at Prevention: The HPV Vaccine and the Politics of Medicine's Simple Solutions. Baltimore, MD: Johns Hopkins University Press, pp. 21-38.
8. Bell, K. (2009) 'If it almost kills you that means it's working': Cultural models of chemotherapy expressed in a cancer support group. Social Science and Medicine 68(1): 169-176.
9. Bell, K. and Kazanjian, A. (2011) PSA testing: Molecular technologies and men's experience of prostate cancer survivorship. Health, Risk & Society 13(2): 183-196.
10. Beaulac, J.A., Fry, R.N. and Onysko, J. (2006) Lifetime and recent prostate-specific antigen (PSA) screening of men for prostate cancer in Canada. Canadian Journal of Public Health 97(3): 171-176. (Pubitemid 44043622)
11. Best, J. (2001) Damned Lies and Statistics: Untangling Numbers from the Media, Politicians and Activists. Berkeley, CA: University of California Press.
12. Biehl, J., Coutinho, D. and Outeiro, A.L. (2001) Technology and affect: HIV/AIDS testing in Brazil. Culture, Medicine and Psychiatry 25(1): 87-129. (Pubitemid 33712801)
13. Chandler, D. (2007) Semiotics: The Basics. London: Routledge.
14. Chitale, R. (2009) Monitoring ovarian cancer: CA125 trial stirs controversy. Journal of the National Cancer Institute 101(8): 1233-1235.
15. Clarke, A.E., Shim, J.K., Mamo, L., Fosket, J.R. and Fishman, J.R. (2003) Biomedicalization: Technoscientific transformations of health, illness, and US biomedicine. American Sociological Review 68(2): 161-194. (Pubitemid 36696071)
16. Clarke, A.E., Mamo, L., Fosket, J.R., Fishman, J.R. and Shim, J.K. (eds.) (2010) Biomedicalization: Technoscience, Health and Illness in the US. Durham, NC: Duke University Press.
17. Clarke, A.E. (2010) From the rise of medicine to biomedicalization: US healthscapes and iconography, circa 1890-present. In: A.E. Clarke, L. Mamo, J.R. Fosket, J.R. Fishman and J. Shim (eds.) Biomedicalization: Technoscience, Health and Illness in the US. Durham, NC: Duke University Press, pp. 104-146.
18. Comaroff, J. and Maguire, P. (1981) Ambiguity and the search for meaning: Childhood leukaemia in the modern clinical context. Social Science & Medicine 15B(2): 115-123. (Pubitemid 11120490)
19. Crawford, R. (1980) Healthism and the medicalization of everyday life. International Journal of Health Services 10(3): 365-388. (Pubitemid 10087469)
20. Crump, T. (1990) The Anthropology of Numbers. Cambridge, UK: Cambridge University Press.
21. Dumit, J. (1999) Objective brains, prejudicial images. Science in Context 12(1): 173-201.
22. Eeles, R.A. and Powles, T.J. (2000) Chemoprevention options for BRCA1 and BRCA2 carriers. Journal of Clinical Oncology 18(21S): 93s-99s.
23. Evans, R., Edwards, A.G.K., Elwyn, G., Watson, E., Grol, R. and Brett, J. (2007) It's a maybe test': Men's experiences of prostate specific antigen testing in primary care. British Journal of General Practice 57(537): 303-310. (Pubitemid 46534194)
24. Fayed, L. (2009) CA-125 test for ovarian cancer, http://cancer.about.com/ od/ovariancancer/a/CA125.htm, accessed 4 May 2012.
25. FORCE. (2011) Cancer previvors. FORCE: Facing Our Risk of Cancer Empowered, http://www.facingourrisk .org/info-research/previvors-survivors/ cancer-previvors/index.php, accessed 12 December 2011.
26. Fosket, J.R. (2010) Breast cancer risk as disease. In: A.E. Clarke, L. Mamo, J.R. Fosket, J.R. Fishman and J. Shim (eds.) Biomedicalization: Technoscience, Health and Illness in the US. Durham, NC: Duke University Press, pp. 331-352.
27. Frank, A. (1991) At the Will of the Body: Reflections on Illness. Boston, MA: Houghton Mifflin.
28. Foucault, M. (1989) The Birth of the Clinic. London: Routledge.
29. Gibbon, S. (2007) Breast Cancer Genes and the Gendering of Knowledge: Science and Citizenship in the Cultural Context of the 'New' Genetics. London: Palgrave Macmillan.
30. Gibbon, S., Kampriani, E. and zur Nieden, A. (2010) BRCA patients in Cuba, Greece and Germany: Comparative perspectives on public health, the state and the partial reproduction of 'neoliberal' subjects. BioSocieties 5(4): 440-466.
31. Gillespie., C. (2012) The experience of risk as 'measured vulnerability': Health screening and lay uses of numerical risk. Sociology of Health & Illness 34(2): 194-207.
32. Guppy, A.E. and Rustin, G.J.S. (2002) CA125 response: Can it replace the traditional response criteria in ovarian cancer? The Oncologist 7(5): 437-443. (Pubitemid 35266136)
33. Hacking, I. (1990) The Taming of Chance. Cambridge, UK: Cambridge University Press.
34. Hamilton, A.B. (1999) Psychological aspects of ovarian cancer. Cancer Investigation 17(5): 335-341. (Pubitemid 29266706)
35. Hewitson, P. and Austoker, J. (2005) Patient information, informed decision-making and the psycho-social impact of prostate-specific antigen testing. British Journal of Urology International 95(S3): 16-32. (Pubitemid 40547264)
36. Hogarth, S., Hopkins,M.M. and Rodriguez, V. (2012) A molecular monopology? HPV testing, the pap smear and the molecularisation of cervical cancer screening in the USA. Sociology of Health & Illness 34(2): 234-250.
37. Howell, D., Fitch, M.I. and Deane, K.A. (2003) Women's experiences with recurrent ovarian cancer. Cancer Nursing 26(1): 10-17. (Pubitemid 36152251)
38. Jain, S.L. (2007) Living in prognosis: Toward an elegiac politics. Representations 98(1): 77-92.
39. Joyce, K. (2010) An examination of the economic and political dynamics of magnetic resonance imaging and the construction of difference. In: A.E. Clarke, L. Mamo, J.R. Fosket, J.R. Fishman and J. Shim (eds.) Biomedicalization: Technoscience, Health and Illness in the US. Durham, NC: Duke University Press, pp. 197-217.
40. Karam, A.K. and Karlan, B.Y. (2010) Ovarian cancer: The duplicity of CA125 measurement. Nature Reviews Clinical Oncology 7(July): 335-339.
41. Kavanagh, A.M. and Broom, D.H. (1997) Embodied risk: My body, myself? Social Science & Medicine 46(3): 437-444. (Pubitemid 28022407)
42. Kleinman, A.M. (1988) The Illness Narratives: Suffering, Healing and the Human Condition. New York: Basic Books.
43. Koocher, G.P. and O'Malley, J.E. (1981) The Damocles Syndrome: Psychosocial Consequences of Surviving Childhood Cancer. New York: McGraw-Hill.
44. Ludwig, J.A. and Weinstein, J.N. (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer 5: 845-856. (Pubitemid 41746029)
45. MacIntyre, R. (1999) Mortal Men: Living with Asymptomatic HIV. Piscataway, NJ: Rutgers University Press.
46. Mamo, L. and Fosket, J.R. (2009) Scripting the body: Pharmaceuticals and the (re)making of menstruation. Signs 34(4): 925-949.
47. Martin, A. and Lynch, M. (2009) Counting things and counting people: The practices and politics of counting. Social Problems 56(2): 243-266.
48. Mayeux, R. (2004) Biomarkers: Potential uses and limitations. NeuroRx 1(2): 182-188. (Pubitemid 46589350)
49. Nerenz, D.R., Leventhal, H. and Love, R.R. (1982) Emotional distress during chemotherapy. Cancer 50(5): 1020-1027.
50. Nessa, J. (1996) About signs and symptoms: Can semiotics expand the view of clinical medicine? Theoretical Medicine 17(4): 363-377. (Pubitemid 27018921)
51. Novas, C. and Rose, N. (2000) Genetic risk and the birth of the somatic individual. Economy and Society 29(4): 485-513.
52. Olaitan, A. (2011) Recommendations for detection in primary care are flawed. British Medical Journal 342: d3022.
53. Palmer, C., Pratt, J., Basu, B. and Earle, H. (2006) A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference. Gynecologic Oncology 101(1): 4-11.
54. Parker, P.A., Kudelka, A., Basen-Engquist, K., Kavanagh, J., de Moor, J. and Cohen, L. (2006) The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecologic Oncology 100(3): 495-500. (Pubitemid 43246864)
55. Paulos, J.A. (1998) Innumeracy: Mathematical Illiteracy and Its Consequences. New York: Hill and Wang.
56. Peirce, C.S. (1894) What is a Sign?, http://www.marxists.org/reference/ subject/philosophy/works/us/peirce1 .html, accessed 19 May 2012.
57. Peirce, C.S. (1905) Letter of Charles S. Peirce to Mario Calderoni on Pragmaticism (L 67, 1905). Universidid de Navarra, http://www.unav.es/gep/ LetterCalderoniEn.html, accessed 10 May 2012.
58. Peirce, C.S. (1931-1958) Collected Papers of Charles Sanders Peirce, 8 volumes. Vols. 1-6, Charles Hartshorne and Paul Weiss (eds.), Vols. 7-8, Arthur W. Burks (ed.), Cambridge, MA: Harvard University Press.
59. Peirce, C.S. (1998) The Essential Peirce. Selected Philosophical Writings, Vol. 2 (1893-1913), The Peirce Edition Project (eds.), Bloomington, IN: Indiana University Press.
60. Petersen, A. and Lupton, D. (1997) The New Public Health: Health and Self in the Age of Risk. London, UK: Sage Publications.
61. Polzer, J. (2000) Genetic testing, citizenship and subjectivity: Implications for women and health. In: F. Miller, L.Weir, R.Mykitiuk, P. Lee, S. Sherwin and S. Tudiver (eds.) The Gender of Genetic Futures: The Canadian Biotechnology Strategy, Women and Health, NNEWH Working Paper Series, Toronto, Canada: York University, pp. 53-63.
62. Porter, T.M. (1995) Trust in Numbers: The Pursuit of Objectivity in Science and Public Life. Princeton, NJ: Princeton University Press.
63. Potter, J., Wetherall, M. and Chitty, A. (1991) Quantification rhetoric - Cancer on television. Discourse and Society 2(3): 333-365.
64. Press, N., Fishman, J.R. and Koenig, B.A. (2000) Collective fear, individualized risk: The social and cultural context of genetic testing for breast cancer. Nursing Ethics 7(3): 237-248.
65. Price, R.W. et al (2007) Biomarkers of HIV-1 CNS infection and injury. Neurology 69(18): 1781-1788. (Pubitemid 350059307)
66. Quote Investigator. (2011) Sometimes a cigar is just a cigar. Quote Investigator: Dedicated to Tracing Quotations, http://quoteinvestigator.com/ 2011/08/12/just-a-cigar/, accessed 30 May 2012.
67. Rabinow, P. (1996) Essays on the Anthropology of Reason. Princeton, NJ: Princeton University Press.
68. Robertson, A. (2001) Biotechnology, political rationality and discourses on health risk. Health 5(3): 293-309. (Pubitemid 33679914)
69. Rose, N. (1993) Government, authority and expertise in advanced liberalism. Economy and Society 22(3): 283-299.
70. Rose, N.S. (1999) Governing the Soul: The Shaping of the Private Self. London, UK: Free Association Books.
71. Rose, N. (2007) The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton, NJ: Princeton University Press.
72. Roskies, A. (2007) Are neuroimages like photographs of the brain? Philosophy of Science 74(5): 860-872.
73. Rossing, K. et al (2008) Urinary proteomics in diabetes and CKD. Journal of the American Society of Nephrology 19(7): 1283-1290.
74. Rustin, G.J. and van der Burg, M.E. on behalf of MRC and EORTC Collaborators (2009) A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). Journal of Clinical Oncology 27(18S): 1.
75. Sachs, L. (1995) Is there a pathology of prevention? The implications of visualizing the invisible in screening programs. Culture, Medicine and Psychiatry 19(4): 503-525.
76. Sachs, L. (1996) Causality, responsibility and blame - Core issues in the cultural construction and subtext of prevention. Sociology of Health & Illness 18(5): 632-652.
77. Sagar, S.M. and Lawenda, B.W. (2009) The role of integrative oncology in a tertiary prevention survivorship program. Preventive Medicine 49(2-3): 93-98.
78. de Saussure, F. (1983) Course in General Linguistics. Chicago, IL: Open Court Publishing.
79. Shostak, S. (2010) Marking populations and persons at risk: Molecular epidemiology and environmental health. In: A.E. Clarke, L. Mamo, J.R. Fosket, J.R. Fishman and J. Shim (eds.) Biomedicalization: Technoscience, Health and Illness in the US. Durham, NC: Duke University Press, pp. 242-262.
80. Staiano-Ross, K. (2007) Wounded warriors: Further explorations into a biocultural semiotics. Semiotica 166(1/4): 1-44.
81. Sulik, G. (2009) Managing biomedical uncertainty: The technoscientific illness identity. Sociology of Health & Illness 30(7): 1059-1076.
82. Sulik, G.A. (2011) 'Our diagnoses, our selves': The rise of the technoscientific illness identity. Sociology Compass 5(6): 463-477.
83. Sulik, G.A. and Eich-Krohm, A. (2008) No longer a patient: the social construction of the medical consumer. In: S.M. Chambré and M. Goldner (eds.) Patients, Consumers and Civil Society: Advances in Medical Sociology, Vol. 10, pp. 3-28.
84. TC-Cancer.com. (2011) Elevated LDH y please help. TC-Cancer.com Support Forum, http://www .tc-cancer.com/forum/showthread.php?t=11747, accessed 31 May 2012.
85. Thorne, S., Hislop, G., Kuo, M. and Armstrong, E-A. (2006) Hope and probability: Patient perspectives of the meaning of numerical information in cancer communication. Qualitative Health Research 16(3): 318-336. (Pubitemid 43263730)
86. Vasan, R.S. (2006) Basic science for clinicians. Biomarkers of cardiovascular disease - molecular basis and practical considerations. Circulation 113: 2335-2362. (Pubitemid 43947980)
87. Wagner, P.J. and Curran, P. (1984) Health beliefs and physician identified 'worried well'. Health Psychology 3(5): 459-474.
88. Watson, E. et al (2006) Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: A randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. Patient Education and Counseling 63(3): 367-379. (Pubitemid 44511880)
89. Woodward, K. (1999) Statistical panic. Differences: A Journal of Feminist Cultural Studies 11(2): 177-203. (Pubitemid 33209673)